title: [Latest advances on the maintenance therapy of multiple myeloma].
abstract: Multiple myeloma (MM) is an uncurable disease. Chemotherapy with standard dose or autologous stem cell transplantation (auto-HSCT) after chemotherapy with high dose is able to induce remission, but relapse still exists. For this reason the ultimate goal of MM treatment is to improve relapse free survival (RFS) and progression free survival (PFS) efficiently. Recently, maintenance therapy made substantial progress in improving progression-free survival and overall survival (OS) of patients with multiple myeloma, especially thalidomide, lenalidomide and bortezomib used in clinic. Here, the latest advances of clinical researches on maintenance therapy of MM are summarized briefly in this review.
authors: Department of Hematoloy, Jiangsu Province Hospital of Traditional Chinese Medicine, The First Clinical Medical College of Nanjing University of Traditional Chinese Medicine, Nanjing 210029, Jiangsu Province, China.
authors: Yun
authors: Y
authors: Zhuang
authors: Department of Hematoloy, Jiangsu Province Hospital of Traditional Chinese Medicine, The First Clinical Medical College of Nanjing University of Traditional Chinese Medicine, Nanjing 210029, Jiangsu Province, China. E-mail: shenq@medmail.com.cn.
authors: Qun
authors: Q
authors: Shen
mesh_terms: D001897:Boronic Acids; D000069286:Bortezomib; D018572:Disease-Free Survival; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma; D011719:Pyrazines; D013792:Thalidomide / Q000031:analogs & derivatives
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D000077269:Lenalidomide